RetatrutideGuide.org — The Definitive Triple-Agonist Research Resource
Where to Buy Retatrutide (GLP3-R) in 2026
Retatrutide (LY3437943) is the first-in-class GLP-1/GIP/GCGR triple-agonist. TRIUMPH-4 Phase III: 28.7% weight loss at 68 weeks — highest ever recorded.
Retatrutide vs Semaglutide vs Tirzepatide
- Retatrutide: 28.7% weight loss (68 wk) — Triple agonist (GLP-1+GIP+GCGR)
- Tirzepatide (Mounjaro/Zepbound): 22.5% (72 wk) — Dual agonist (GLP-1+GIP)
- Semaglutide (Wegovy/Ozempic): 15-17% (68 wk) — GLP-1 only
Key Clinical Results (April 2026)
- TRIUMPH-4 Phase III (Dec 2025): 28.7% body weight reduction, 71.2 lbs lost at 12mg dose
- TRANSCEND-T2D-1 (Mar 2026): 2.0% HbA1c reduction, 16.8% weight loss in type 2 diabetes
- Phase II (NEJM 2023): 24.2% weight loss at 48 weeks, no plateau observed
- FDA NDA submission: Q4 2026-Q1 2027
Research-Grade Retatrutide
BioInfinity Lab GLP3-R: 99%+ purity, third-party COA verified, GMP compliant. Buy GLP3-R — Use code RETA20 for 20% off.
Frequently Asked Questions
How much weight can you lose on Retatrutide? Up to 28.7% body weight (71.2 lbs) at 68 weeks based on Phase III TRIUMPH-4 data.
Is Retatrutide better than Ozempic? Retatrutide produces roughly double the weight loss (28.7% vs 15-17%) through its triple mechanism.
When will Retatrutide be FDA approved? NDA submission estimated Q4 2026-Q1 2027, commercial availability ~2028.